High Prevalence of Echocardiographic Abnormalities among HIV-infected Persons in the Era of Highly Active Antiretroviral Therapy.
暂无分享,去创建一个
J. Gottdiener | J. Brooks | E. Overton | K. Mondy | P. Patel | E. Kojic | T. Bush | K. Henry | J. Hammer | L. Conley | C. Carpenter
[1] Michael J Silverberg,et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. , 2009, The New England journal of medicine.
[2] H. Hense,et al. The aging process of the heart: obesity is the main risk factor for left atrial enlargement during aging the MONICA/KORA (monitoring of trends and determinations in cardiovascular disease/cooperative research in the region of Augsburg) study. , 2009, Journal of the American College of Cardiology.
[3] I. Aban,et al. Risk behaviours in HIV-positive men who have sex with men participating in an intervention in a primary care setting , 2009, International journal of STD & AIDS.
[4] J. Meigs,et al. Association of C-Reactive Protein and HIV Infection With Acute Myocardial Infarction , 2009, Journal of acquired immune deficiency syndromes.
[5] E. Overton,et al. Factors associated with renal dysfunction within an urban HIV‐infected cohort in the era of highly active antiretroviral therapy , 2009, HIV medicine.
[6] P. Lin,et al. Roles and mechanisms of human immunodeficiency virus protease inhibitor ritonavir and other anti-human immunodeficiency virus drugs in endothelial dysfunction of porcine pulmonary arteries and human pulmonary artery endothelial cells. , 2009, The American journal of pathology.
[7] K. Wood,et al. The study to understand the natural history of HIV and AIDS in the era of effective therapy (SUN Study). , 2008, American journal of epidemiology.
[8] J. Lundgren. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients , 2008, AIDS.
[9] Peter Reiss,et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. , 2008, JAMA.
[10] R. Parker,et al. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. , 2008, Journal of the American College of Cardiology.
[11] G. Mensah,et al. Screening and assessment of coronary heart disease in HIV-infected patients. , 2008, Circulation.
[12] O. Kirk,et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration , 2008, The Lancet.
[13] C. Sabin,et al. Antiretroviral drugs and the risk of myocardial infarction - Reply , 2007 .
[14] O. Kirk,et al. Class of antiretroviral drugs and the risk of myocardial infarction. , 2007, The New England journal of medicine.
[15] J Darbyshire,et al. CD4+ count-guided interruption of antiretroviral treatment. , 2006, The New England journal of medicine.
[16] James B Seward,et al. Left atrial size: physiologic determinants and clinical applications. , 2006, Journal of the American College of Cardiology.
[17] William Stewart,et al. Recommendations for chamber quantification. , 2006, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.
[18] B. Lau,et al. C-reactive protein is a marker for human immunodeficiency virus disease progression. , 2006, Archives of internal medicine.
[19] Richard B Devereux,et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[20] S. Colan,et al. Mild dilated cardiomyopathy and increased left ventricular mass predict mortality: the prospective P2C2 HIV Multicenter Study. , 2005, American heart journal.
[21] G. Behrens. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. , 2005, The New England journal of medicine.
[22] D. Kitzman,et al. Contribution of left ventricular diastolic dysfunction to heart failure regardless of ejection fraction. , 2005, The American journal of cardiology.
[23] S. Hammer,et al. C-Reactive protein levels over time and cardiovascular risk in HIV-infected individuals suppressed on an indinavir-based regimen: AIDS Clinical Trials Group 5056s , 2004, AIDS.
[24] J. Gardin,et al. American Society of Echocardiography recommendations for use of echocardiography in clinical trials. , 2004, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[25] R. Speich,et al. Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[26] Vilmundur Gudnason,et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. , 2004, The New England journal of medicine.
[27] K. Bailey,et al. Association of newer diastolic function parameters with age in healthy subjects: a population-based study. , 2003, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[28] S. Oka,et al. Dilated cardiomyopathy in an adult human immunodeficiency virus type 1-positive patient treated with a zidovudine-containing antiretroviral regimen. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[29] Anne L. Taylor,et al. Coronary heart disease in HIV-infected individuals. , 2003, Journal of acquired immune deficiency syndromes.
[30] P. Tebas,et al. Emerging bone problems in patients infected with human immunodeficiency virus. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[31] Douglas W Mahoney,et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. , 2003, JAMA.
[32] James B Seward,et al. Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. , 2002, The American journal of cardiology.
[33] K. Dingemans,et al. Cardiomyopathy with mitochondrial damage associated with nucleoside reverse-transcriptase inhibitors. , 2002, The New England journal of medicine.
[34] John M Williamson,et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1 , 2002, The Lancet.
[35] D. Vlahov,et al. Use of HIV protease inhibitors is associated with left ventricular morphologic changes and diastolic dysfunction. , 2002, Journal of acquired immune deficiency syndromes.
[36] B. Horne,et al. Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. , 2002, The American journal of cardiology.
[37] Arthur E. Weyman,et al. Clinical Correlates and Reference Intervals for Pulmonary Artery Systolic Pressure Among Echocardiographically Normal Subjects , 2001, Circulation.
[38] R. Lancashire,et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study , 2001, The Lancet.
[39] M. Schambelan,et al. Metabolic effects of indinavir in healthy HIV-seronegative men , 2001, AIDS.
[40] R. D'Agostino,et al. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. , 2001, The Journal of clinical endocrinology and metabolism.
[41] O. Turriziani,et al. Changes in host cell molecules acquired by circulating HIV-1 in patients treated with highly active antiretroviral therapy and interleukin-2 , 2001, AIDS.
[42] E. Pujol,et al. Ventricular mass and diastolic function in patients infected by the human immunodeficiency virus , 2000, Heart.
[43] R. Raddino,et al. Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement. , 2000, The Journal of infection.
[44] James N Gribble,et al. Interview Mode and Measurement of Sexual Behaviors: Methodological Issues. , 1999, Journal of sex research.
[45] G. Barbarini,et al. Incidence of dilated cardiomyopathy and detection of HIV in myocardial cells of HIV-positive patients. Gruppo Italiano per lo Studio Cardiologico dei Pazienti Affetti da AIDS. , 1998, The New England journal of medicine.
[46] K. Miller,et al. Visceral abdominal-fat accumulation associated with use of indinavir , 1998, The Lancet.
[47] R. Speich,et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. , 1997, American journal of respiratory and critical care medicine.
[48] M. Domanski,et al. Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus. , 1995, The Journal of pediatrics.
[49] S. Daniels,et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. , 1992, Journal of the American College of Cardiology.
[50] N. Schiller,et al. Noninvasive estimation of right atrial pressure from the inspiratory collapse of the inferior vena cava. , 1990, The American journal of cardiology.
[51] D. Buff. Primary pulmonary hypertension. , 1987, Annals of internal medicine.
[52] Amalio Telenti,et al. Antiretroviral Treatment of Adult HIV Infection2010 Recommendations of the International AIDS Society–USA Panel , 2010 .
[53] S. Hammer,et al. Antiretroviral Treatment of Adult HIV Infection 2008 Recommendations of the International AIDS Society–USA Panel , 2008 .
[54] G. Simonneau,et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. , 2008, American journal of respiratory and critical care medicine.